Medicare negotiation of drug prices would stifle the development of much-needed therapies. Curtailing defensive medicine and rolling back excessive regulation would be a better way to control healthcare costs.
Michael Abrams, MA
Advertisement
Co-founder of Numerof & Associates
Articles by Michael Abrams, MA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
In AI vs. Humans, AI Can ‘Surpass’ and By Far | AAO 2025
2
Eylea HD Provides Vision Gains and Longer Dosing Intervals in Real-World Analysis | AAO 2025
3
El Niño and La Niña Affect Eye Health Too, Not Just Weather | AAO 2025
4
AI and Ophthalmology: A Nearly Picture Perfect Kinda Match | AAO 2025
5
